Clinical and Imaging Biomarkers in Parkinsonian Syndromes

We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.

Who Should Attend?

This webinar is suitable job titles in the following departments:

  • Chief Medical/Scientific Officer

  • Heads of: R&D, Clinical Research, Clinical Development, Clinical Operations

  • TA Head/Lead

  • Clinical Lead

  • Medical Monitors

  • Clinical Scientists

  • Imaging Scientist

  • Biomarkers Scientists

  • Study/Project Manager

  • Clinical OperationsDirector/Manager

  • Protocol Manager

  • Study Startup

  • Procurement/Outsourcing

What You Will Learn

  • A clinical overview of parkinsonian syndromes with a focus on Parkinson’s disease (PD), multiple systems atrophy (MSA) and progressive supranuclear palsy (PSP)

  • Addressing diagnostic challenges when recruiting for clinical trials

  • Overview of the use of current imaging biomarkers in clinical trials in Parkinson's disease

  • Introduction to emerging imaging biomarkers in Parkinson's disease


Horacio Kaufmann, MD, Professor, Department of Neurology, Medicine, and Pediatrics, NYU Langone Health. Director, Division of Autonomic Disorders (Neurology) NYU Grossman School of Medicine

Dr. Horacio Kaufmann is Professor of Neurology, Medicine and Pediatrics and holds the F.B. Axelrod Chair for Neurological Research at New York University School of Medicine where he also heads the division of Autonomic Disorders and the Dysautonomia Center at NYU Langone Health. Dr. Kaufmann received his medical degree from the National University of Buenos Aires, Argentina. He trained in Internal Medicine and completed Neurology residency and fellowship at Mount Sinai School of Medicine in New York City.

Dr. Kaufmann is one of the world’s foremost experts and a leader in the field of autonomic disorders including Parkinson’s disease and multiple system atrophy. His research focuses on the autonomic nervous system and its abnormalities in neurological disorders, and he has conducted innovative clinical trials of the main drugs used in the treatment of these disorders.

Hiba Kazmi, PhD, Associate Biomarker Scientist, IXICO

Dr. Hiba Kazmi graduated from King’s College London with a Master’s degree in Clinical Neuroscience and holds a PhD from University College London (UCL) Queen Square Institute of Neurology. Her PhD investigated the presence of clinical and imaging features associated with prodromal Parkinson’s Disease in patients with late onset depression. She also has experience in clinical settings, including working with patients with psychiatric disorders such as depression and schizophrenia.

Hiba currently works at IXICO as an Associate Biomarker Scientist, across a range of therapeutic areas including Parkinson’s disease, Progressive Supranuclear Palsy and Alzheimer’s disease.

Date: 18/05/2021